Alvotech Reaches Licensing Settlement with Regeneron and Bayer on Eylea Biosimilar
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Yahoo Finance
- Patent Dispute Resolution: Alvotech has reached a settlement with Regeneron and Bayer, resolving all patent disputes related to its Eylea® biosimilar, enabling global production and supply, which is expected to significantly enhance market competitiveness.
- Market Access Timeline: Under the agreement, Alvotech's biosimilar will launch in the UK and Canada on January 1, 2026, addressing urgent market needs for effective treatments and further solidifying its position in the global market.
- Strategic Partnerships: Alvotech's commercial partners in Europe include Advanz Pharma, STADA, and Biogaran, which will facilitate faster market introduction of the new product and enhance the company's influence in the biosimilar sector.
- Product Approval Status: The Eylea biosimilar has been approved for marketing in Europe and Japan under the names Mynzepli® and AFLIBERCEPT BS, respectively, which is expected to generate substantial revenue streams and promote the sustainability of global healthcare systems.
Analyst Views on ALVO
Wall Street analysts forecast ALVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALVO is 8.60 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
3 Buy
1 Hold
1 Sell
Moderate Buy
Current: 5.310
Low
5.00
Averages
8.60
High
10.00
Current: 5.310
Low
5.00
Averages
8.60
High
10.00
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
